Navigation Links
GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
Date:10/29/2008

PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) (LSE: GSK) and Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).

Under the terms of the agreement, a subsidiary of GSK will commence a tender offer to acquire all of the outstanding shares of Genelabs common stock. The board of directors of Genelabs has unanimously recommended that shareholders tender their shares in the offer.

"Genelabs has demonstrated a strong track record in HCV drug discovery and identified numerous novel classes of inhibitors that target unprecedented mechanisms in the virus's life cycle," stated Zhi Hong, SVP of the Infectious Diseases Centre for Excellence in Drug Discovery (ID CEDD) at GSK. "This arrangement, combined with our other collaborations, will give GSK a broad HCV drug discovery platform addressing novel targets and innovative therapeutic approaches."

Genelabs will become part of GSK's Drug Discovery organization and its HCV programs will be consolidated into the broad therapeutic approaches already underway internally and through external collaborations. This acquisition continues GSK's strategy of pursuing the best science, internally or externally, to bring new medicines to patients and value to the GSK pipeline.

Fred Driscoll, President & CEO of Genelabs said, "This transaction provides our shareholders with certain value at a substantial premium to our stoc
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
2. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
3. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
4. GlaxoSmithKline To Post Quarterly US Grants Report
5. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
6. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
7. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
8. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
9. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
10. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
11. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... (PRWEB) August 18, 2014 Global HIV ... pharma report announced by Reportstack. The rate of HIV infection ... on a declining note at a positive rate across the ... from 2.3 million in 2005 to 1.5 in 2013, with ... cause for such drastic changes in the infection rates has ...
(Date:8/18/2014)... , Aug. 18, 2014 TNI BioTech, ... company pioneering the manufacturing and marketing of innovative therapies ... the Company is providing a second notice of TNI ... In making the announcement, Noreen Griffin , founder ... in advance for your participation in the Annual Meeting. ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
(Date:8/16/2014)... a way to make atomic-force microscope probes 20 times ... as the weight of an individual virus. , The ... (ANU), hinges on using laser beams to cool a ... level of sensitivity achieved after cooling is accurate enough ... virus that is 100 billion times lighter than a ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4Laser makes microscopes way cooler 2
... , , , ... Healthcare today released new survey results revealing that 85 percent of ... concern. Yet, when asked about testing their children for allergies, ... options available. Furthermore, more than one-third were not familiar with the ...
... , London, July 20 There has been a ... and biotechnology space. While the economic downturn and related credit crunch ... M&A mania, which has including four mega M&As in the first ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , "The ...
... , , COLUMBIA, Md., July 17 ... DHA, Martek Biosciences (Nasdaq: MATK ), announced today that it ... Food Chain and Animal Health (SCFCAH) of the European Union for additional ... , This is a significant action that will provide ...
Cached Biology Technology:American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 2American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 3American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 4American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 5Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities 2EU Committee Approves New Food Applications for Martek's life'sDHA(TM) 2EU Committee Approves New Food Applications for Martek's life'sDHA(TM) 3
(Date:8/19/2014)... and other science courses are increasingly being asked ... they have a new textbook to help them ... this month by Princeton Press and co-authored by ... Biological Synthesis (NIMBioS), teaches readers about basic mathematical ... explore and explain biological phenomena. , Suitable for ...
(Date:8/19/2014)... a glass of fizzy soda knows that bubbles can ... finding with wide industrial applications, Princeton researchers have demonstrated ... the liquid as well. , "It is well known ... surprised, and fascinated, to discover that when we covered ... oil droplets into the water," said Howard Stone, the ...
(Date:8/19/2014)... 19 August 2014: An engineer at the University of ... having a brain to communicate with the body. , ... L Mahadevan, has developed a mathematical model for earthworms ... how these soft bodied animals get around. , The ... pattern generator (CPG) which states that the central brain ...
Breaking Biology News(10 mins):New textbook introduces undergraduates to mathematics for the life sciences 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3Secrets of how worms wriggle uncovered 2
... TXService learning involves the incorporation of community service into ... In the service learning model, students participate in ,real ... community. Researchers T.M. Waliczek and J.M. Zajicek reported on ... horticulture course in HortTechnology . The team found ...
... June 23, 2011 UT Southwestern Medical Center ... signaling pathway in Huntington,s disease, a finding that may ... slow the progression of degenerative nerve disorders. "Our ... disease treatment and possibly for other neurodegenerative diseases," said ...
... began working with legendary drug developer Paul Janssen, founder of ... an effort to create new and potent drugs to fight ... second anti-HIV drug that came from this collaboration., "For ... countless obstacles must be overcome," said Eddy Arnold, Board of ...
Cached Biology News:Service projects increase learning, social impact for undergrads 2Compound may provide drug therapy approach for Huntington's disease 2Rutgers laboratory helped to create new HIV drug 2Rutgers laboratory helped to create new HIV drug 3